|
1
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Ervik M, Lam F, Colombet M, Mery
L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global cancer
observatory: Cancer today. International Agency for Research on
Cancer; Lyon: 2018
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martins EB, Chojniak R, Kowalski LP,
Nicolau UR, Lima EN and Bitencourt AG: Diffusion-weighted MRI in
the assessment of early treatment response in patients with
squamous-cell carcinoma of the head and neck: Comparison with
morphological and PET/CT Findings. PLoS One. 10:e01400092015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harashavardhan NS, Naveen Kumar S, Uday
Kumar NS, Ezhilarasi R and Bhavani B: A prospective analysis of
magentic resonance imaging and computed tomography in staging with
uterine cervix carcinoma: A single centre experience. J Chalmeda
Anand Rao Institute Med Sci. 16:158–162. 2018.
|
|
8
|
Lee SI, Catalano OA and Dehdashti F:
Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT,
and PET/MR imaging. J Nucl Med. 56:436–443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gee MS, Atri M, Bandos AI, Mannel RS, Gold
MA and Lee SI: Identification of distant metastatic disease in
uterine cervical and endometrial cancers with FDG PET/CT: Analysis
from the ACRIN 6671/GOG 0233 multicenter trial. Radiology.
287:176–184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dolgun ZN, Altintas AS, Ivan C and
Balkanli P: Comparison of preoperative magnetic resonance imaging
results with postoperative pathologic results in early stage
uterine cervical cancer. Eur J Gynaecol Oncol. 39:935–938.
2018.
|
|
11
|
Herrera FG and Prior JO: The role of
PET/CT in cervical cancer. Front Oncol. 3:342013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramlov A, Kroon PS, Jurgenliemk-Schulz IM,
Leeuw AA, Gormsen LC, Fokdal LU, Tanderup K and Lindegaard JC:
Impact of radiation dose and standardized uptake value of (18)FDG
PET on nodal control in locally advanced cervical cancer. Acta
Oncol. 54:1567–1573. 2015. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI
|
|
13
|
Selman TJ, Mann C, Zamora J, Appleyard TL
and Khan K: Diagnostic accuracy of tests for lymph node status in
primary cervical cancer: A systematic review and meta-analysis.
CMAJ. 178:855–862. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salvatici M, Achilarre MT, Sandri MT,
Boveri S, Vanna Z and Landoni F: Squamous cell carcinoma antigen
(SCC-Ag) during follow-up of cervical cancer patients: Role in the
early diagnosis of recurrence. Gynecol Oncol. 142:115–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimura K, Mabuchi S, Yokoi T, Sasano T,
Sawada K, Hamasaki T and Kimura T: Utility of serum squamous cell
carcinoma antigen levels at the time of recurrent cervical cancer
diagnosis in determining the optimal treatment choice. J Gynecol
Oncol. 24:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu J, Wang W, Wang Y, Liu C and Wang P:
The role of squamous cell carcinoma antigen (SCC Ag) in outcome
prediction after concurrent chemoradiotherapy and treatment
decisions for patients with cervical cancer. Radiat Oncol.
14:1462019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Choi KH, Lee SW, Yu M, Jeong S, Lee JW and
Lee JH: Significance of elevated SCC-Ag level on tumor recurrence
and patient survival in patients with squamous-cell carcinoma of
uterine cervix following definitive chemoradiotherapy: A
multi-institutional analysis. J Gynecol Oncol. 30:e12019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang EY, Huang YJ, Chanchien CC, Lin H,
Wang CJ, Sun LM, Tseng CW, Tsai CC, Ou YC, Fu HC, et al:
Pretreatment carcinoembryonic antigen level is a risk factor for
para-aortic lymph node recurrence in addition to squamous cell
carcinoma antigen following definitive concurrent chemoradiotherapy
for squamous cell carcinoma of the uterine cervix. Radiat Oncol.
7:132012.
|
|
19
|
Kang S, Nam BH, Park JY, Seo SS, Ryu SY,
Kim JW, Kim SC, Park SY and Nam JH: Risk assessment tool for
distant recurrence after platinum-based concurrent chemoradiation
in patients with locally advanced cervical cancer: A Korean
gynecologic oncology group study. J Clin Oncol. 30:2369–2374. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pieterse QD, Kenter GG, Maas CP, de Kroon
CD, Creutzberg CL, Trimbos JB and Kuile MM: Self-reported sexual,
bowel and bladder function in cervical cancer patients following
different treatment modalities: Longitudinal prospective cohort
study. Int J Gynecol Cancer. 23:1717–1725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiao XB, Hu J and Zhu LR: The safety of
ovarian preservation in early-stage adenocarcinoma compared with
squamous cell carcinoma of uterine cervix: A systematic review and
meta-analysis of observational studies. Int J Gynecol Cancer.
26:1510–1514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim TH, Kim MH, Kim BJ, Park SI, Ryu SY
and Cho CK: Prognostic importance of the site of recurrence in
patients with metastatic recurrent cervical cancer. Int J Radiat
Oncol Biol Phys. 98:1124–1131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bhatla N, Aoki D, Sharma DN and
Sankaranarayanan R: Cancer of the cervix uteri. Int J Gynaecol
Obstet. 143 (Suppl 2):S22–S36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Salani R, Khanna N, Frimer M, Bristow RE
and Chen LM: An update on post-treatment surveillance and diagnosis
of recurrence in women with gynecologic malignancies: Society of
gynecologic oncology (SGO) recommendations. Gynecol Oncol.
146:3–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yilmaz B, Dağ S, Ergul N and Çermik TF:
The efficacy of pretreatment and after treatment 18F-FDG PET/CT
metabolic parameters in patients with locally advanced squamous
cell cervical cancer. Nucl Med Commun. 40:219–227. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Yuan S, Wang L, Sun X, Hu X, Meng X
and Yu J: Diagnostic and predictive value of using RGD PET/CT in
patients with cancer: A systematic review and meta-analysis. Biomed
Res Int. 2019:85347612019.PubMed/NCBI
|
|
27
|
Kitajima K, Suzuki K, Nakamoto Y, Onishi
Y, Sakamoto S, Senda M, Kita M and Sugimura K: Low-dose
non-enhanced CT versus full-dose contrast-enhanced CT in integrated
PET/CT studies for the diagnosis of uterine cancer recurrence. Eur
J Nucl Med Mol Imaging. 37:1490–1498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sironi S, Picchio M, Landoni C, Galimberti
S, Signorelli M, Bettinardi V, Perego P, Mangioni C, Messa C and
Fazio F: Post-therapy surveillance of patients with uterine
cancers: Value of integrated FDG PET/CT in the detection of
recurrence. Eur J Nucl Med Mol Imaging. 34:472–479. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bentivegna E, Uzan C, Gouy S, Leboulleux
S, Duvillard P, Lumbroso J, Haie-Meder C, Schlumberger M and Morice
P: Correlation between [18f]fluorodeoxyglucose positron-emission
tomography scan and histology of pelvic nodes in early-stage
cervical cancer. Anticancer Res. 30:1029–1032. 2010.PubMed/NCBI
|
|
30
|
Chou HH, Chang TC, Yen TC, Ng KW, Hsueh S,
Ma SY, Chang CJ, Huang HJ, Chao A, Wu TI, et al: Low value of
[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in
primary staging of early-stage cervical cancer before radical
hysterectomy. J Clin Oncol. 24:123–128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Driscoll DO, Halpenny D, Johnston C,
Sheehy N and Keogan M: 18F-FDG-PET/CT is of limited value in
primary staging of early stage cervical cancer. Abdom Imaging.
40:127–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maffione AM, Piva M, Tsamita CS, Nanni C,
Castellucci P, Ambrosini V, Lopci E, Musto A, Rampin L, Grassetto
G, et al: Positron-emission tomography in gynaecologic
malignancies. Arch Gynecol Obstet. 280:521–528. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chong A, Ha JM, Jeong SY, Song HC, Min JJ,
Bom HS and Choi HS: Clinical usefulness of (18)F-FDG PET/CT in the
detection of early recurrence in treated cervical cancer patients
with unexplained elevation of serum tumor markers. Chonnam Med J.
49:20–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan L, Cheng J, Zhou M, Yao Z and Zhang Y:
The SUVmax (maximum standardized uptake value for F-18
fluorodeoxyglucose) and serum squamous cell carcinoma antigen
(SCC-ag) function as prognostic biomarkers in patients with primary
cervical cancer. J Cancer Res Clin Oncol. 138:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
